SURMOUNT 2, OASIS 1 and other trial symposia lead program at ADA Scientific Sessions
Click Here to Manage Email Alerts
Key takeaways:
- The ADA 83rd Scientific Sessions will take place Friday through Monday in San Diego.
- The conference will feature trial results for tirzepatide, semaglutide and a GIP/GLP-1/glucagon receptor triagonist.
Findings from several pivotal trials, including SUMOUNT-2, OASIS-1 and PIONEER PLUS, will be among the many highlights at the American Diabetes Association’s 83rd Scientific Sessions beginning Friday.
The ADA Scientific Sessions will take place Friday through Monday at the San Diego Convention Center. For the second consecutive year, the ADA will be hosting a hybrid meeting with more than 100 sessions livestreamed for people wishing to watch sessions from home. Some sessions are not being livestreamed, but will be available on demand 2 months after the conclusion of the meeting.
According to Marlon Pragnell, PhD, vice president of research and science at the ADA, there are advantages to both in-person and virtual meetings and Pragnell said he believes that hosting a hybrid meeting provides the best of both worlds for those attending the Scientific Sessions.
“The scale and substance of the ADA Scientific Sessions, there’s so much information there and it’s such a big meeting with so many topics and areas that there’s no way a person can see everything,” Pragnell said. “This allows people the comfort of knowing that they can meet people, engage in conversation and still follow up on the presentations they may have missed.”
Another change is the length of the meeting and the symposia themselves. Based on feedback from past meeting attendees, Pragnell said, the ADA opted to shorten this year’s meeting to 4 days and also cut down the length of the symposia from 2 hours to 90 minutes.
This year’s Scientific Sessions will have several late-breaking symposia with new data from several key diabetes and obesity trials. One of the biggest sessions will take place Friday at 3:45 p.m. PST as data will be presented from the SURMOUNT-2 trial on the effects of tirzepatide (Mounjaro, Eli Lilly) for adults with obesity and type 2 diabetes. As Healio previously reported, top-line results from SURMOUNT-2 released by Elil Lilly in April revealed 15 mg tirzepatide conferred 15.7% weight loss for participants.
Findings from the two trials will be featured during a late-breaking symposium Sunday at 4:30 p.m. PST. Results will be presented from the OASIS-1 and PIONEER PLUS trials on oral semaglutide (Rybelsus, Novo Nordisk) for the treatment of obesity and type 2 diabetes. Findings from the SURMOUNT-2, OASIS-1 and PIONEER PLUS trials will be simultaneously published in The Lancet at the time of the presentation.
Another late-breaking symposium scheduled for Monday at 1:30 p.m. PST will focus on the novel GIP/GLP-1/glucagon receptor triagonist retatrutide (Eli Lilly). The presentation will examine the drug’s impact on obesity, nonalcoholic fatty liver disease and type 2 diabetes in phase 2 trial data.
“With these incretin-based drugs, we’re seeing a significant improvement in glycemic control and on top of that, we’re seeing this impressive weight loss,” Pragnell said. “Now, an area it could benefit is nonalcoholic steatohepatitis or fatty liver disease. What’s going to happen is, as we see more and more of these incretin-based drugs being studied, we’re going to see some really interesting [benefits].”
Other highlights in this year’s meeting include the following (all times Pacific Standard Time):
- The conference will kick off Friday at 10:30 a.m. with a keynote address from former NIH director Francis Collins, MD, PhD. The opening session will be followed by a symposium titled “Pathway to Stop Diabetes” at 11:30 a.m.
- The COORDINATE trial will take center stage Monday at 1:30 p.m. as findings will be presented from the trial’s diabetes study. Pragnell said the symposium is one of several sessions at this year’s conference that will focus on the simultaneous treatment of cardiovascular health and diabetes to improve outcomes for patients.
- Attendees will be able to learn about the development of some of the newest diabetes drugs during the President, Medicine & Science Address and Banting Medal for Achievement presentation Sunday at 9:45 a.m.. This year’s Banting Medal recipient, Matthias Tschöp, MD, will discuss some of his research that paved the way for the development of dual agonists.
- All attendees are invited to a networking reception Friday at 6:30 p.m. in the exhibit hall. The reception will be an opportunity for attendees to preview the poster hall, reconnect with colleagues and network with other experts in the field of diabetes.
“I’m looking forward to hearing the reports on the trials,” Pragnell said. “I’m really looking forward to the immediate dissemination of this information out to the world. I’m also looking forward to seeing people enjoying the meeting, getting value out of it, experiencing great research and just being invigorated and excited by all of the knowledge and engagement.”
The Healio | Endocrine Today staff will provide live coverage from the ADA Scientific Sessions with reports on the presentations, video interviews and more. For more information on the agenda and registration, visit professional.diabetes.org/scientific-sessions.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts